New Psoriasis Drug Shows Promise

Tuesday, 25 October 2011 10:26 AM

Rapid and significant relief of moderate-to-severe psoriasis symptoms has been reported in trials of the new Novartis drug AIN457, the pharmaceutical company says.

In one study, 81 percent of patients receiving AIN457 subcutaneously once a month showed at least a 75 percent improvement – compared to just 9 percent improvement by the group receiving a placebo after 12 weeks.

"We are encouraged by these positive Phase II results and look forward to receiving the results of larger-scale and longer-term Phase III studies with AIN457 which began this year," said John Hohneker, global head of development for integrated hospital care at Novartis.

AIN457 is a human antibody designed to suppress the inflammation involved in a number of immune-mediated diseases, including psoriasis.

Psoriasis is a common hereditary disease characterized by thick skin lesions called plaques. Symptoms associated with the lesions including itching, scaling, and pain. Psoriasis affects about 2 percent of the world’s population.

© HealthDay

1Like our page
Tuesday, 25 October 2011 10:26 AM
Newsmax Media, Inc.

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved